Novartis has entered into an agreement to acquire Regulus Therapeutics, a clinical-stage biopharmaceutical company focused on developing microRNA therapeutics. 

Regulus’ lead asset, farabursen, is a next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD). 

“With limited treatment options currently available for patients suffering from ADPKD, farabursen represents a potential first-in-class medicine with a profile that may provide enhanced efficacy, tolerability and safety versus standard of care,” said Shreeram Aradhye, President, Development and Chief Medical Officer, Novartis. “ADPKD is the most common genetic cause of renal failure worldwide. The team at Regulus has done meaningful foundational work with farabursen, and we look forward to investigating its potential further as we aim to bring a better treatment option to patients in need.” 

Farabursen is an investigational microRNA inhibitor designed to target miR-17 with preferential kidney exposure, aiming to reduce the growth of cysts and kidney size, as well as delay progression of disease severity in ADPKD.  

In March 2025, Regulus announced the successful completion of its Phase Ib multiple-ascending dose clinical trial for farabursen.  

The Phase Ib trial data showed promising clinical efficacy and safety, including consistent impact on urinary polycystin (PC), a biomarker of mechanistic response, and height-adjusted total kidney volume (htTKV), a measure of progressive disease. 

Under the terms of the transaction, holders of Regulus common stock will receive $7 per share at closing and up to $7 per share payable upon the achievement of a regulatory milestone. 

The transaction is expected to close in the second half of 2025, when Regulus will become an indirect wholly owned subsidiary of Novartis. 

Diana Spencer, Senior Digital Content Editor, DDW